CURRENT DATA ON THE ROLE OF HOMOCYSTEINE IN THE FORMATION OF CARDIOVASCULAR DISEASES
DOI: https://doi.org/10.29296/25877305-2024-03-11
Issue:
3
Year:
2024
Recent research has made it possible to expand and complement the modern understanding of the regulation of many physiological processes of the body. At the same time, there are many controversial questions about the role of increasing homocysteine levels in the development of certain diseases, mainly cardiovascular pathology.
Purpose. To analyze the current literature on the contribution of hyperhomocysteinemia to the formation of cardiovascular diseases (CVD).
Material and methods. The data of foreign and domestic articles on the research topic found in Pubmed and eLibrary and published over the past 7 years are analyzed.
Conclusions. Hyperhomocysteinemia leads to amplification of the adverse effects of classical CVD risk factors such as hypertension, smoking, lipid metabolism by participating in the formation of endothelial dysfunction.
Keywords:
homocysteine
cardiovascular risk
folate cycle gene polymorphism
vitamin B12
folic acid.
References:
- Roth G.A., Mensah G.A., Johnson C.O. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76: 2982–3021. DOI: 10.1016/j.jacc.2020.11.010
- Azzini E., Ruggeri S., Polito A. Homocysteine: Its Possible Emerging Role in At-Risk Population Groups. Int J Mol Sci. 2020; 21 (4): 1421. DOI: 10.3390/ijms21041421
- Wakabayashi I. Homocysteine Levels and Arterial Stiffness in the General Population. J Atheroscler Thromb. 2016; 23 (6): 668–70. DOI: 10.5551/jat.ED043
- Isakov V.A., Bogdanova A.A., Bessonov V.V. et al. Effects of Multivitamin, Multimineral and Phytonutrient Supplementation on Nutrient Status and Biomarkers of Heart Health Risk in a Russian Population: A Randomized, Double Blind, Placebo Controlled Study. Nutrients. 2018; 10 (2): 120. DOI: 10.3390/nu10020120
- Mantjoro E.M., Toyota K., Kanouchi H. Positive Association of Plasma Homocysteine Levels with Cardio-Ankle Vascular Index in a Prospective Study of Japanese Men from the General Population. J Atheroscler Thromb. 2016; 23 (6): 681–91. DOI: 10.5551/jat.32243
- Dong Y., Huang T., Zhai Z. et al. Lowering serum homocysteine in H-type hypertensive patients with atrial fibrillation after radiofrequency catheter ablation to prevent atrial fibrillation recurrence. Front Nutr. 2022; 9: 995838. DOI: 10.3389/fnut.2022.995838
- Esse R., Barroso M., Tavares de Almeida I. et al. The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art. Int J Mol Sci. 2019; 20 (4): 867. DOI: 10.3390/ijms20040867
- Hermann A., Sitdikova G. Homocysteine: Biochemistry, Molecular Biology and Role in Disease. Biomolecules. 2021; 11 (5): 737. DOI: 10.3390/biom11050737
- Rizzo G., Laganà A.S. The Link between Homocysteine and Omega-3 Polyunsaturated Fatty Acid: Critical Appraisal and Future Directions. Biomolecules. 2020; 10 (2): 219. DOI: 10.3390/biom10020219
- Jakubowski H. Homocysteine Modification in Protein Structure/Function and Human Disease. Physiol Rev. 2019; 99 (1): 555–604. DOI: 10.1152/physrev.00003.2018
- Maron B.A., Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med. 2009; 60: 39–54. DOI: 10.1146/annurev.med.60.041807
- Angelini A., Cappuccilli M.L., Magnoni G. et al. The link between homocysteine, folic acid and vitamin B12 in chronic kidney disease. G Ital Nefrol. 2021; 38 (4): 2021-vol4.
- Guéant J.L., Guéant-Rodriguez R.M., Oussalah A. et al. Hyperhomocysteinemia in Cardiovascular Diseases: Revisiting Observational Studies and Clinical Trials. Thromb Haemost. 2023; 123 (3): 270–82. DOI: 10.1055/a-1952-1946
- Zaric B.L., Obradovic M., Bajic V. Homocysteine and Hyperhomocysteinaemia. Curr Med Chem. 2019; 26 (16): 2948–61. DOI: 10.2174/0929867325666180313105949
- Besen S., Ozkale Y., Ceylaner S. et al. Clinical and laboratory findings and etiologies of genetic homocystinemia: a single-center experience. Acta Neurol Belg. 2024; 124 (1): 213–22. DOI: 10.1007/s13760-023-02356-1
- Jakubowski H. Homocysteine editing, thioester chemistry, coenzyme A, and the origin of coded peptide synthesis dagger. Life. 2017; 7: 6. DOI: 10.3390/life7010006
- Gurda D., Handschuh L., Kotkowiak W. et al. Homocysteine thiolactone and N-homocysteinylated protein induce pro-atherogenic changes in gene expression in human vascular endothelial cells. Amino Acids. 2015; 47: 1319–39. DOI: 10.1007/s00726-015-1956-7
- Perła-Kaján J., Borowczyk K., Głowacki R. et al. Paraoxonase 1 Q192R genotype and activity affect homocysteine thiolactone levels in humans. FASEB J. 2018; 32: 6019–24. DOI: 10.1096/fj.201800346R
- Borowczyk K., Piechocka J., Głowacki R. et al. Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: The WENBIT trial. J Intern Med. 2019; 285: 232–44. DOI: 10.1111/joim.12834
- Bosevski M., Zlatanovikj N., Petkoska D. et al. Plasma Homocysteine in Patients with Coronary and Carotid Artery Disease: A Case Control Study. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2020; 41 (1): 15–22. DOI: 10.2478/prilozi-2020-0019
- Chen L., Wang B., Wang J. et al. et al. Association between serum total homocysteine and arterial stiffness in adults: a community-based study. J Clin Hypertens (Greenwich). 2018; 20 (4): 686–93. DOI: 10.1111/jch.13246
- Li W.X., Cheng F., Zhang A.J. et al. Folate Deficiency and Gene Polymorphisms of MTHFR, MTR and MTRR Elevate the Hyperhomocysteinemia. Risk Clin Lab. 2017; 63: 523–33. DOI: 10.7754/Clin.Lab.2016.160917
- Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med. 2022; 23 (2): 73. DOI: 10.31083/j.rcm2302073
- Karolczak K., Watala C. Melatonin as a Reducer of Neuro- and Vasculotoxic Oxidative Stress Induced by Homocysteine. Antioxidants (Basel). 2021; 10 (8): 1178. DOI: 10.3390/antiox10081178
- Gaiday A.N., Tussupkaliyev A.B.T., Bermagambetova S.K. et al. Effect of homocysteine on pregnancy: A systematic review. Chem Biol Interact. 2018; 293: 70–6. DOI: 10.1016/j.cbi.2018.07.021
- Tinelli C., Di Pino A., Ficulle E. et al. Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies. Front Nutr. 2019; 6: 49. DOI: 10.3389/fnut.2019.00049
- Cimmino G., Natale F., Alfieri R. et al. Non-Conventional Risk Factors: "Fact" or "Fake" in Cardiovascular Disease Prevention? Biomedicines. 2023; 11 (9): 2353. DOI: 10.3390/biomedicines11092353
- Mallikethi-Reddy S., Briasoulis A., Akintoye E. et al. Novel biomarkers with potential for cardiovascular risk reclassification. Biomarkers. 2017; 22 (3-4): 189–99. DOI: 10.1080/1354750X.2016.1201540
- Senousy S.M., Farag M.K., Gouda A.S. et al. Association Between Biomarkers of Vitamin B12 Status and the Risk of Neural Tube Defects. J Obstet Gynaecol Res. 2018; 44: 1902–8. DOI: 10.1111/jog.13751